Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need

A newly launched grass roots campaign aimed at academics and the biotech community offers some insight into Sanofi's reinvigorated R&D organization, which is meant to be more flexible and entrepreneurial. Despite the potential upheaval caused by its recent $20.1 billion acquisition of Genzyme, Sanofi is talking up a handful of targeted areas of high unmet need and commensurately huge opportunities that are a critical part of its long-range strategy.

Ever since December 2010, when Sanofi, which recently dropped the Aventis portion of its name, announced former National Institutes of Health Director Elias Zerhouni was spearheading the French pharma's R&D initiatives, outsiders have expected major changes in how the firm will approach innovation. A newly launched grass roots campaign aimed at academics and the biotech community offers some insight into the French pharma's reinvigorated R&D organization, which is meant to be more flexible and entrepreneurial. Despite the potential upheaval caused by its recent $20.1 billion acquisition of Genzyme Corp., Sanofi is talking up a handful of targeted areas of high unmet need and commensurately huge opportunities that are a critical part of its long-range strategy. [See Deal] ( See "Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now," IN VIVO, March 2011 Also see "Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now " - In Vivo, 1 March, 2011..)

Sanofi actually announced its reworked R&D structure in June 2009, about six months after Christopher Viehbacher took over as CEO....

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo